Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of VaxemHIB in Healthy Chinese Children
NCT01125527Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2009
- Primary completion
- Oct 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of VaxemHIB in Haemophilus influenzae type b infection (Hib) (2 arms), sponsored by Novartis. Primary endpoint: Anti-PRP antibody levels at day 31 post last vaccination. Started Aug 2009; status: completed.
02
Drugs
VaxemHIB
03
Conditions
Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT01125527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125527.